NASDAQ:CTMX

Cytomx Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CTMX

*Your capital is at risk

$3.22

+0.0600 (+1.90%)

At Close: Jun 03, 2026

CytomX Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 8.56. In total, the insiders bought 9.01M and sold 616.05K CTMX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	8.56
● Buy	9.01M shares
● Sell	616.05K shares
77% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Mar 17, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 17, 2026 Sell	Common Stock S-Sale	Belvin Marcia SVP, Chief Scientific Officer	Officer	31 492 Value: $202.3K
Mar 17, 2026 Sell	Common Stock S-Sale	Chu Yu-waye Chief Medical Officer	Officer	21 279 Value: $136.7K
Mar 17, 2026 Sell	Common Stock S-Sale	Mccarthy Sean A. CEO	CEO / President	118 969 Value: $764.1K
Mar 17, 2026 Sell	Common Stock S-Sale	Ogden Christopher Chief Financial Officer	C-Suite Officer	19 323 Value: $124.1K
Feb 02, 2026 Buy	Common Stock A-Award	Mccarthy Sean A. CEO	CEO / President	210 000 Value: $1.28M
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Ogden Christopher Chief Financial Officer	C-Suite Officer	325 000 Value: $1.98M
Feb 02, 2026 Buy	Common Stock A-Award	Belvin Marcia SVP, Chief Scientific Officer	Officer	60 000 Value: $365.4K
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Lester Rachael Chief Business Officer	Officer	50 000 Value: $304.5K
Feb 02, 2026 Buy	Performance Stock Units (PSUs) A-Award	Lester Rachael Chief Business Officer	Officer	50 000 Value: $304.5K
Feb 02, 2026 Buy	Common Stock A-Award	Lester Rachael Chief Business Officer	Officer	20 000 Value: $121.8K
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Chu Yu-waye Chief Medical Officer	Officer	300 000 Value: $1.83M
Feb 02, 2026 Buy	Common Stock A-Award	Chu Yu-waye Chief Medical Officer	Officer	75 000 Value: $456.8K
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Belvin Marcia SVP, Chief Scientific Officer	Officer	250 000 Value: $1.52M
Feb 02, 2026 Buy	Common Stock A-Award	Ogden Christopher Chief Financial Officer	C-Suite Officer	90 000 Value: $548.1K
Feb 02, 2026 Buy	Stock Option (Right to Buy) A-Award	Mccarthy Sean A. CEO	CEO / President	980 000 Value: $5.97M
Nov 06, 2025 Sell	Class A Common Stock S-Sale	Mccarthy Sean A. CEO	CEO / President	101 793 Value: $461.9K
Oct 20, 2025 Buy	Common Stock J-Other	Lester Rachael Insider	Other	0 Value: $0
Oct 20, 2025 Buy	Stock Option (Right to Buy) A-Award	Lester Rachael Chief Business Officer	Officer	650 000 Value: $2.43M
Sep 26, 2025 Buy	Stock Option (Right to Buy) A-Award	Mccarthy Sean A. CEO	CEO / President	570 000 Value: $1.65M
Sep 26, 2025 Buy	Performance Stock Units (PSUs) A-Award	Mccarthy Sean A. CEO	CEO / President	285 000 Value: $826.5K
Sep 26, 2025 Buy	Stock Option (Right to Buy) A-Award	Chu Yu-waye Chief Medical Officer	Officer	87 500 Value: $253.8K
Sep 26, 2025 Buy	Performance Stock Units (PSUs) A-Award	Chu Yu-waye Chief Medical Officer	Officer	43 750 Value: $126.9K
Sep 26, 2025 Buy	Stock Option (Right to Buy) A-Award	Ogden Christopher Chief Financial Officer	C-Suite Officer	78 250 Value: $226.9K
Sep 26, 2025 Buy	Performance Stock Units (PSUs) A-Award	Ogden Christopher Chief Financial Officer	C-Suite Officer	39 150 Value: $113.5K
Sep 26, 2025 Buy	Stock Option (Right to Buy) A-Award	Belvin Marcia SVP, Chief Scientific Officer	Officer	36 300 Value: $105.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CYTOMX THERAPEUTICS

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme...

Read Full Profile Here